Cholangitis (Cholangiohepatitis) in Cats — Management Guide

Practical, evidence-based guide to diagnosing and managing feline cholangitis (neutrophilic and lymphocytic forms), triaditis links, diagnostics, drug choices (antibiotics vs immunosuppression), ursodiol, and prognosis.

Quick Overview

• What it is: Cholangitis (also called cholangiohepatitis) in cats is inflammation of the bile ducts and adjacent liver tissue. Two main histologic patterns are recognized: neutrophilic (suppurative) cholangitis, typically bacterial and often acute, and lymphocytic (chronic nonsuppurative) cholangitis, often immune-mediated and chronic.
• Who's at risk: Any age of cat can be affected, but middle-aged to older cats are most commonly diagnosed. Cats with inflammatory bowel disease (IBD) and pancreatitis (the “triaditis” syndrome) are at higher risk because of shared duct anatomy and potential ascending infection.
• Prognosis: Variable. Many cats with neutrophilic cholangitis improve rapidly with targeted antibiotics and supportive care; long-term outcome is often good if treated early. Lymphocytic cholangitis tends to be chronic and may require lifelong immunosuppression; prognosis depends on response to therapy and degree of fibrosis at diagnosis.

Pathophysiology (Explained Simply)

• Anatomy: In cats the common bile duct and pancreatic duct often join or open close together at the duodenum. That anatomic arrangement allows intestinal bacteria or pancreatic inflammation to affect the biliary system.
• Neutrophilic (suppurative) cholangitis: Usually results from ascending bacterial infection from the intestine into the biliary tree. Neutrophils infiltrate bile ducts and bile; bacteria are commonly isolated from bile or liver in many affected cats.
• Lymphocytic (chronic nonsuppurative) cholangitis: Characterized by lymphocyte-predominant inflammation and is thought to be immune-mediated, often associated with chronic inflammatory disease in the gut (IBD) and/or pancreas.
• Chronic changes: Persistent inflammation can lead to bile duct hyperplasia, fibrosis, and progressive loss of functional liver tissue.

• No strong single-breed predisposition is firmly established. Domestic short-haired and long-haired cats are most commonly reported simply because they are common breeds.
• Some reports suggest an overrepresentation of middle-aged to older cats; Siamese and Persian cats have been described in some small case series but breed risk is not well-defined in large population studies.
• Triaditis (IBD + pancreatitis + cholangitis) occurs relatively commonly in cats — concurrent disease should be considered in any cat with hepatobiliary signs.

Common clinical signs

• Lethargy, anorexia, weight loss
• Vomiting and/or diarrhea (common with triaditis)
• Jaundice (yellow mucous membranes/skin) in moderate–severe disease
• Fever (more common with suppurative disease)
• Abdominal pain, often palpable discomfort in cranial abdomen
• Pale stools (cholestasis) or dark urine

• Acute neutrophilic cholangitis: often more severe and rapid in onset, frequently febrile, may cause marked elevations in liver enzymes and bilirubin.
• Chronic lymphocytic cholangitis: insidious onset, waxing and waning clinical signs, more likely to show chronic changes on biopsy and liver enzyme abnormalities.

Goals: confirm hepatobiliary inflammation, determine neutrophilic vs lymphocytic pattern where possible, identify infectious causes (bacterial culture), assess severity and concurrent disease (IBD/pancreatitis).

1) Baseline clinicopathologic tests

• CBC: may show neutrophilia with left shift in suppurative cases, anemia of chronic disease in chronic cases.
• Serum biochemistry: ALT commonly elevated (hepatocellular injury). ALP and GGT may be increased (cholestasis); hyperbilirubinemia indicates more severe cholestasis.
• Bile acids and coagulation profile (PT/PTT) if hepatic dysfunction suspected.

• Abdominal ultrasound: assesses biliary tract (bile duct dilation or wall thickening), gallbladder (sludge, wall thickening, choleliths), and pancreas; ultrasound guides cholecystocentesis and biopsies.

• Ultrasound-guided cholecystocentesis to obtain bile for cytology and aerobic/anaerobic culture +/- sensitivity is strongly recommended in suspected neutrophilic cholangitis. Bile culture often yields the causative bacteria (e.g., E. coli, Enterococcus, Bacteroides species).

• Liver biopsy is the gold standard to distinguish neutrophilic versus lymphocytic cholangitis and to stage the degree of fibrosis. Options:

• Histopathology identifies the inflammatory pattern and severity and helps guide therapy (antibiotics vs immunosuppression).

• Pancreatic lipase immunoreactivity (fPLI) for pancreatitis; fecal or serum testing for intestinal disease; consider intestinal biopsies if IBD suspected.

• If biopsy is required and your veterinarian lacks surgical or laparoscopic capability.
• If biliary surgery is being considered (cholecystectomy) or cholecystostomy is needed.
• For difficult-to-control or refractory disease requiring advanced immunosuppression or long-term monitoring.

Principles

• Treat the underlying cause: bacteria for neutrophilic cases, immune-mediated inflammation for lymphocytic cases.
• Supportive care for anorexia, vomiting, dehydration, and hepatic dysfunction.
• Use bile acid therapy and hepatoprotectants as adjuncts.

• Always aim to culture bile or liver if possible and direct antibiotics using susceptibility testing.
• Empirical choices (until culture results available):

• Duration: typically at least 4–6 weeks, sometimes longer depending on clinical response, ultrasound, and lab improvements. Re-evaluate with serial bloodwork and ultrasound; stop only after clinical and biochemical resolution and completion of an appropriate course.

• Prednisolone is the first-line agent: common starting dose 1–2 mg/kg/day PO (or 0.5–1 mg/kg/day if diabetic or fragile), with gradual tapering to the lowest effective maintenance dose.
• Steroid-sparing or adjunctive agents if inadequate response or unacceptable steroid side effects:

• Note: Azathioprine is not recommended in cats (high risk of toxicity).

• Mechanism: choleretic (improves bile flow), cytoprotective, may help reduce cholestasis.
• Typical dosing: 8–15 mg/kg/day divided every 12–24 hours (commonly 10–15 mg/kg/day). Adjust by response and tolerance.
• Use caution or avoid if complete biliary obstruction is present.

• Antiemetics (maropitant 1 mg/kg PO/SC q24h; ondansetron 0.5–1 mg/kg IV/SC) for vomiting.
• Analgesia (buprenorphine 0.01–0.02 mg/kg IV/IM/SL) for abdominal pain.
• Hepatoprotectants: SAMe (S‑adenosylmethionine) 20 mg/kg PO q24h; silymarin/milk thistle products (dosing product-dependent).
• Vitamin K if coagulopathy or hypocoagulable.
• Nutritional support: appetite stimulants, assisted feeding if anorexic.

• Indicated for gallbladder rupture, obstructive cholelithiasis, or when cholecystectomy is required. Cholecystectomy can be curative if disease localized to gallbladder.
• Surgical biliary bypass/stenting is uncommon in cats and high-risk.

• Regular rechecks: initially every 1–2 weeks until stable, then every 1–3 months. Monitor CBC, serum biochemistry (ALT, ALP, GGT, bilirubin), bile acids as indicated.
• Repeat abdominal ultrasound to assess biliary appearance and for resolution of ductal dilation or gallbladder abnormalities.
• If on long-term steroids or immunosuppressives, monitor for adverse effects (polyuria, polydipsia, weight gain, diabetes, secondary infections).
• Adjust diet if concurrent IBD or pancreatitis: easily digestible, moderate to low-fat diets may help if pancreatitis coexists. For chronic liver disease consider veterinary hepatic-support diets under guidance.
• Owners should monitor appetite, activity, vomiting, stool quality, urine color, and mucous membrane color.

• Neutrophilic cholangitis: Many cats respond well to appropriate antibiotics and supportive care; if treated early, the prognosis is often good. Relapses can occur, especially if concurrent intestinal disease persists.
• Lymphocytic cholangitis: Tends to be chronic; many cats respond to immunosuppression (prednisolone ± adjuncts) but may require lifelong therapy and monitoring. Some progress to hepatic fibrosis and failure despite treatment.
• Overall quality of life can be good when disease is controlled. Early diagnosis and treatment improve the likelihood of a favorable outcome.

• Medication adherence: Give antibiotics, prednisone, ursodiol, and any adjuncts exactly as prescribed; do not stop steroids abruptly.
• Observe for relapse signs: decreased appetite, vomiting, jaundice, lethargy — report these promptly.
• Diet: Feed small, palatable meals. If pancreatitis is present, follow low-fat recommendations from your veterinarian.
• Minimize stress and monitor for side effects of long-term meds (increased drinking/urination, behavior changes).
• Keep follow-up appointments for bloodwork and imaging as scheduled — these detect relapse or medication side effects early.

Seek immediate veterinary attention if your cat develops:

• Marked jaundice (yellow gums/eyes/skin)
• Repeated vomiting, inability to keep water down
• Severe lethargy, collapse, or seizures (possible hepatic encephalopathy)
• New or worsening abdominal pain
• Bleeding (nosebleeds, bleeding from gums) or bruising

Evidence base and sources

• Clinical practice for cholangitis in cats is informed by veterinary hepatology reviews and case series; diagnostic and therapeutic approaches prioritize bile/liver culture and histopathology to distinguish neutrophilic vs lymphocytic disease, and use bile acids/ursodiol and targeted antibiotics or immunosuppression accordingly.
• Selected resources: Merck Veterinary Manual (Cholangitis/Cholangiohepatitis in Cats), ACVIM specialty guidelines and peer-reviewed reviews in the Journal of Feline Medicine and Surgery and Journal of Veterinary Internal Medicine for specifics on sampling, antibiotic choices, and immunosuppressive regimens.

Frequently Asked Questions